NCI-2023-01949

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants withSelect Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

This Phase 1 study is investigating a drug called PRT3789 in participants diagnosed with specific advanced or metastatic solid tumors that have a mutation in the SMARCA4 gene. The study is open-label and conducted at multiple centers, meaning that both participants and researchers are aware of the treatment being administered. The main objectives of the study are to assess the safety and effectiveness of PRT3789 in treating these types of tumors with SMARCA4 mutations.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05639751

Clinical Trial Site: Columbia

To see all available clinical trials click here.